Open an account

Wellgistics Health

MEDS · NASDAQ

$2.75+$0.08 (+3.00%)TodayMarket closed ·
Prev close $2.67

About MEDS

Wellgistics Health, Inc. operates as a holding company centered around pharmaceuticals and healthcare services. The company is headquartered in Tampa, Florida. The company went IPO on 2025-02-21. The company focuses on specialty medications and a community-based model offering home delivery services to patients. The company is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows for clinical services to be connected to the Company’s health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, improve prescription price transparency, and provide additional concierge services. Its products include Kyzatrex and Semaglutide and Tirzepatide.

Employees
31
Headquarters
Tampa, Florida
Listed
Feb 21, 2025
Sector
Health Care
Industry
Health Care Providers & Services
Website
wellgisticshealth.com

MEDS key statistics

Market cap
11.99M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.37M
Volume
218.04K
Open price
$2.62
High today
$2.78
Low today
$2.58
52 Week high
$12.31
52 Week low
$0.8225

Wellgistics Health (MEDS) at a glance

Wellgistics Health (MEDS) last traded at $2.75, with a market cap of 11.99M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.58 and $2.78. The current price is 6.6% above the day's low and 1.1% below its high.

Volume so far is 218.04K shares, below the average of 4.37M shares a day.

Over the past year Wellgistics Health has ranged from $0.8225 to $12.31, and now sits 17% of the way up that range.

Wellgistics Health met or beat analyst EPS estimates in 2 of the last 2 quarters. In Q1 FY26 it reported -$0.08 per share against an estimate of -$0.2244.

MEDS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 2 quarters, by 62.9% on average.

  1. Q4 FY25: reported -$0.11 per share against an estimate of -$0.2856
  2. Q1 FY26: reported -$0.08 per share against an estimate of -$0.2244

MEDS news

  • Vandana Singh

    DataMeds AI Stock Rises After Humana Adds Medicaid Coverage for ChemoFx Cancer Test

  • Press releaseACCESS Newswire

    Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment

  • Press releaseGlobe Newswire

    These Stocks Roar into October with Fresh Catalysts

  • Press releaseGlobe Newswire

    4 Explosive Stories Enter the Investor Spotlight

  • Henry Khederian

    DataMeds AI Stock Surges on Mobile App Launch

  • Mohd Haider

    'We Don't Know What the Risks Are': GLP-1 Pill Boom Fuels Hundreds of Apps, but Research Is Lagging

  • Market-Moving News for September 18th

  • Shivdeep Dhaliwal

    Nebius Group, DataMEDS AI, Boeing, Generac Holdings and Delixy Holdings: Why These 5 Stocks Are on Investors' Radars Today

Similar companies

Companies in the same industry as Wellgistics Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.